Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

Authors

Elif Çakan
Olivia D Lara
Anna Szymanowska
Emine Bayraktar
Arturo Chavez-Reyes
Gabriel Lopez-Berestein
Paola Amero
Cristian Rodriguez-Aguayo

Publication Date

8-23-2024

Journal

Cancers

Abstract

Advancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics have emerged as a promising frontier in this realm, offering novel avenues for intervention such as RNA interference and the utilization of antisense oligonucleotides (ASOs). ASOs represent a versatile class of therapeutics capable of selectively targeting messenger RNAs (mRNAs) and silencing disease-associated proteins, thereby disrupting pathogenic processes at the molecular level. Recent advancements in chemical modification and carrier molecule design have significantly enhanced the stability, biodistribution, and intracellular uptake of ASOs, thereby bolstering their therapeutic potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, and parasitic diseases, our review manuscript focuses specifically on the application of ASOs in targeted cancer therapies. Through a comprehensive examination of the latest research findings and clinical developments, we delve into the intricacies of ASO-based approaches to cancer treatment, shedding light on their mechanisms of action, therapeutic efficacy, and prospects.

Keywords

antisense oligonucleotides, non-coding RNA, antisense oligonucleotide delivery system, cancer therapy, Grb2

Comments

PMID: 39272802